Nalaganje...
How I treat relapsed or refractory AML
Treatment of relapsed or refractory acute myeloid leukemia (AML) has presented challenges for hematologists for decades. Despite numerous clinical studies, outcomes are consistently disappointing with 5-year overall survival rates of ∼10%. Allogeneic hematopoietic cell transplantation at the time of...
Shranjeno v:
| izdano v: | Blood |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7453152/ https://ncbi.nlm.nih.gov/pubmed/32518943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001982 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|